Bayer: Edoxaban results in AF : not a threat for xaralto

News published on November Wednesday 20, 2013
Share on

Yesterday, Daiichi Sankyo presented the complete data for edoxaban, the latest new oral anticoagulant, in the ENGAGE AF TIMI 48 study. The data showed that edoxaban met its primary endpoint of non-inferiority on efficacy compared to Warfarin for the prevention of stroke or systemic embolic events in patients with non-valvular atrial fibrillation. We consider that these results are broadly close to those of the ROCKET AF study by Bayer, the ARISTOTLE study by Pfizer and the RELY student essay on Pradaxa by Boehringer Ingelheim. Thus we do not move our figures and maintain our peak sales on Xarelto from Bayer at EUR2.5m in 2021. We maintain our BUY recommendation.

Full report available to subscribers
Please contact   

The Essentials

Everything you need to know about investment banking dedicated to growth
Recent Transactions Highlights
From M&A, to IPOs see what’s been happening at Bryan, Garnier & Co this year
Join our Team
Bryan, Garnier & Co is always looking for talent in all our divisions, at all levels
Explore our opportunities